Kong Wencui, Feng Xuegang, Yu Zongyang, Qi Xingfeng, Zhao Zhongquan
Department of Respiratory, Fuzong Clinical Medical College of Fujian Medical University/The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China.
Department of Cardio-Thoracic Surgery, Fuzong Clinical Medical College of Fujian Medical University/The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China.
Thorac Cancer. 2025 Jan;16(1):e15485. doi: 10.1111/1759-7714.15485. Epub 2024 Nov 17.
Protein tyrosine kinase 7 (PTK7) has been found to be highly expressed in non-small cell lung cancer (NSCLC), but its specific molecular mechanism needs to be further explored.
PTK7 mRNA expression in NSCLC tumor tissues was examined by quantitative real-time PCR. The protein levels of PTK7, ubiquitin-specific peptidase 8 (USP8), PIK3CB, and PI3K/AKT were determined by western blot. Human monocytes (THP-1) were induced into macrophages and then co-cultured with the conditioned medium of NSCLC cells. Macrophage M2 polarization was assessed by detecting CD206 cells using flow cytometry. The interaction between PTK7 and USP8 or PIK3CB was assessed by Co-IP assay. Animal study was performed to evaluate the effects of PTK7 knockdown and PIK3CB on NSCLC tumorigenesis in vivo.
PTK7 expression was higher in NSCLC tumor tissues and cells. After silencing of PTK7, NSCLC cell proliferation, invasion, and macrophage M2 polarization were inhibited, while cell apoptosis was promoted. USP8 enhanced PTK7 protein expression by deubiquitination, and the repressing effects of USP8 knockdown on NSCLC cell growth, invasion, and macrophage M2 polarization were reversed by PTK7 overexpression. PTK7 interacted with PIK3CB, and PIK3CB overexpression could abolish the regulation of PTK7 silencing on NSCLC cell progression. USP8 positively regulated PIK3CB expression by PTK7, thus activating PI3K/AKT pathway. Downregulation of PTK7 reduced NSCLC tumorigenesis by decreasing PIK3CB expression.
USP8-deubiquitinated PTK7 facilitated NSCLC malignant behavior via activating the PIK3CB/PI3K/AKT pathway, providing new idea for NSCLC treatment.
已发现蛋白酪氨酸激酶7(PTK7)在非小细胞肺癌(NSCLC)中高表达,但其具体分子机制有待进一步探索。
采用定量实时PCR检测NSCLC肿瘤组织中PTK7 mRNA表达。通过蛋白质印迹法测定PTK7、泛素特异性肽酶8(USP8)、PIK3CB和PI3K/AKT的蛋白水平。将人单核细胞(THP-1)诱导为巨噬细胞,然后与NSCLC细胞的条件培养基共培养。通过流式细胞术检测CD206细胞来评估巨噬细胞M2极化。通过免疫共沉淀法评估PTK7与USP8或PIK3CB之间的相互作用。进行动物研究以评估PTK7敲低和PIK3CB对体内NSCLC肿瘤发生的影响。
PTK7在NSCLC肿瘤组织和细胞中表达较高。PTK7沉默后,NSCLC细胞增殖、侵袭和巨噬细胞M2极化受到抑制,而细胞凋亡得到促进。USP8通过去泛素化增强PTK7蛋白表达,PTK7过表达可逆转USP8敲低对NSCLC细胞生长、侵袭和巨噬细胞M2极化的抑制作用。PTK7与PIK3CB相互作用,PIK3CB过表达可消除PTK7沉默对NSCLC细胞进展的调节作用。USP8通过PTK7正向调节PIK3CB表达,从而激活PI3K/AKT通路。PTK7的下调通过降低PIK3CB表达减少了NSCLC肿瘤发生。
USP8去泛素化的PTK7通过激活PIK3CB/PI3K/AKT通路促进NSCLC恶性行为,为NSCLC治疗提供了新思路。